Published in Nature on May 15, 2003
Endocrine regulation of energy metabolism by the skeleton. Cell (2007) 10.41
Endocrine regulation of male fertility by the skeleton. Cell (2011) 3.20
miR-214 targets ATF4 to inhibit bone formation. Nat Med (2012) 3.01
Repression of Runx2 function by TGF-beta through recruitment of class II histone deacetylases by Smad3. EMBO J (2005) 2.35
Osteoblast differentiation and skeletal development are regulated by Mdm2-p53 signaling. J Cell Biol (2006) 2.27
The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer. Biochim Biophys Acta (2012) 2.05
Sox2 induction by FGF and FGFR2 activating mutations inhibits Wnt signaling and osteoblast differentiation. J Cell Biol (2005) 2.00
The bone-specific expression of Runx2 oscillates during the cell cycle to support a G1-related antiproliferative function in osteoblasts. J Biol Chem (2005) 1.93
Calcification in atherosclerosis: bone biology and chronic inflammation at the arterial crossroads. Proc Natl Acad Sci U S A (2003) 1.87
Cdh1 regulates osteoblast function through an APC/C-independent modulation of Smurf1. Mol Cell (2011) 1.87
Control of bone formation by the serpentine receptor Frizzled-9. J Cell Biol (2011) 1.77
FoxO1 is a positive regulator of bone formation by favoring protein synthesis and resistance to oxidative stress in osteoblasts. Cell Metab (2010) 1.72
Rapid-throughput skeletal phenotyping of 100 knockout mice identifies 9 new genes that determine bone strength. PLoS Genet (2012) 1.64
A paradigm of integrative physiology, the crosstalk between bone and energy metabolisms. Mol Cell Endocrinol (2009) 1.64
Hematopoietic stem cells regulate mesenchymal stromal cell induction into osteoblasts thereby participating in the formation of the stem cell niche. Stem Cells (2008) 1.58
Loss of MMP-2 disrupts skeletal and craniofacial development and results in decreased bone mineralization, joint erosion and defects in osteoblast and osteoclast growth. Hum Mol Genet (2007) 1.56
Akt1 in osteoblasts and osteoclasts controls bone remodeling. PLoS One (2007) 1.56
Wnt inhibitors Dkk1 and Sost are downstream targets of BMP signaling through the type IA receptor (BMPRIA) in osteoblasts. J Bone Miner Res (2010) 1.54
WISP-1 is an osteoblastic regulator expressed during skeletal development and fracture repair. Am J Pathol (2004) 1.53
Impaired gastric acidification negatively affects calcium homeostasis and bone mass. Nat Med (2009) 1.52
Fat's loss is bone's gain. J Clin Invest (2004) 1.47
The Fos-related antigen Fra-1 is an activator of bone matrix formation. EMBO J (2004) 1.46
Ablation of the Sam68 RNA binding protein protects mice from age-related bone loss. PLoS Genet (2005) 1.44
Canonical Wnts function as potent regulators of osteogenesis by human mesenchymal stem cells. J Cell Biol (2009) 1.44
Bone regeneration and stem cells. J Cell Mol Med (2011) 1.41
Synaptotagmin VII regulates bone remodeling by modulating osteoclast and osteoblast secretion. Dev Cell (2008) 1.38
Enhanced bone formation in lipodystrophic PPARgamma(hyp/hyp) mice relocates haematopoiesis to the spleen. EMBO Rep (2004) 1.37
Smad4 is required for maintaining normal murine postnatal bone homeostasis. J Cell Sci (2007) 1.37
TGF-beta type II receptor phosphorylates PTH receptor to integrate bone remodelling signalling. Nat Cell Biol (2010) 1.33
N-cadherin interacts with axin and LRP5 to negatively regulate Wnt/beta-catenin signaling, osteoblast function, and bone formation. Mol Cell Biol (2008) 1.27
Transcription factor C/EBPbeta isoform ratio regulates osteoclastogenesis through MafB. EMBO J (2009) 1.26
Canonical Wnt signaling inhibits osteoclastogenesis independent of osteoprotegerin. J Cell Biol (2013) 1.24
Pinpointing beta adrenergic receptor in ageing pathophysiology: victim or executioner? Evidence from crime scenes. Immun Ageing (2013) 1.24
Cthrc1 is a positive regulator of osteoblastic bone formation. PLoS One (2008) 1.24
Postnatally induced inactivation of Osterix in osteoblasts results in the reduction of bone formation and maintenance. Bone (2009) 1.23
Zfp521 antagonizes Runx2, delays osteoblast differentiation in vitro, and promotes bone formation in vivo. Bone (2008) 1.19
The high mobility group transcription factor Sox8 is a negative regulator of osteoblast differentiation. J Cell Biol (2005) 1.19
Eph receptors and ephrin signaling pathways: a role in bone homeostasis. Int J Med Sci (2008) 1.17
The osteoprotective effect of Herba epimedii (HEP) extract in vivo and in vitro. Evid Based Complement Alternat Med (2005) 1.16
Expression, signaling, and function of P2X7 receptors in bone. Purinergic Signal (2009) 1.13
Extracellular microfibrils control osteoblast-supported osteoclastogenesis by restricting TGF{beta} stimulation of RANKL production. J Biol Chem (2010) 1.13
Enhanced osteoclast development in collagen-induced arthritis in interferon-gamma receptor knock-out mice as related to increased splenic CD11b+ myelopoiesis. Arthritis Res Ther (2004) 1.10
Zfp521 controls bone mass by HDAC3-dependent attenuation of Runx2 activity. J Cell Biol (2010) 1.10
Mechanisms underlying the osteo- and adipo-differentiation of human mesenchymal stem cells. ScientificWorldJournal (2012) 1.09
OstemiR: a novel panel of microRNA biomarkers in osteoblastic and osteocytic differentiation from mesencymal stem cells. PLoS One (2013) 1.09
Rebalancing bone turnover in favour of formation with strontium ranelate: implications for bone strength. Rheumatology (Oxford) (2008) 1.08
Suppression of osteoclastogenesis through phosphorylation of eukaryotic translation initiation factor 2 alpha. J Bone Miner Metab (2013) 1.08
FIAT represses ATF4-mediated transcription to regulate bone mass in transgenic mice. J Cell Biol (2005) 1.07
Redundant miR-3077-5p and miR-705 mediate the shift of mesenchymal stem cell lineage commitment to adipocyte in osteoporosis bone marrow. Cell Death Dis (2013) 1.07
Type XII collagen regulates osteoblast polarity and communication during bone formation. J Cell Biol (2011) 1.06
CYR61 regulates BMP-2-dependent osteoblast differentiation through the {alpha}v{beta}3 integrin/integrin-linked kinase/ERK pathway. J Biol Chem (2010) 1.05
Generation and selection of novel fully human monoclonal antibodies that neutralize Dickkopf-1 (DKK1) inhibitory function in vitro and increase bone mass in vivo. J Biol Chem (2010) 1.04
Pathogenesis beyond the cancer clone(s) in multiple myeloma. Blood (2015) 1.04
Neighbor of Brca1 gene (Nbr1) functions as a negative regulator of postnatal osteoblastic bone formation and p38 MAPK activity. Proc Natl Acad Sci U S A (2010) 1.03
Zinc may increase bone formation through stimulating cell proliferation, alkaline phosphatase activity and collagen synthesis in osteoblastic MC3T3-E1 cells. Nutr Res Pract (2010) 1.02
A role for ethanol-induced oxidative stress in controlling lineage commitment of mesenchymal stromal cells through inhibition of Wnt/beta-catenin signaling. J Bone Miner Res (2010) 1.02
Negative regulation of bone formation by the transmembrane Wnt antagonist Kremen-2. PLoS One (2010) 1.00
Epidermal growth factor signalling and bone metastasis. Br J Cancer (2009) 0.98
Targeting polymer therapeutics to bone. Adv Drug Deliv Rev (2012) 0.98
Fibroblast growth factor signaling uses multiple mechanisms to inhibit Wnt-induced transcription in osteoblasts. Mol Cell Biol (2008) 0.96
Retinoic acid regulates commitment of undifferentiated mesenchymal stem cells into osteoblasts and adipocytes. J Bone Miner Metab (2012) 0.96
Tissue-engineered models of human tumors for cancer research. Expert Opin Drug Discov (2015) 0.95
Wnt and the Wnt signaling pathway in bone development and disease. Front Biosci (Landmark Ed) (2014) 0.94
Comparison of molecular profiles of human mesenchymal stem cells derived from bone marrow, umbilical cord blood, placenta and adipose tissue. Int J Mol Med (2015) 0.94
Inactivation of glycogen synthase kinase-3β is required for osteoclast differentiation. J Biol Chem (2011) 0.94
A phytoestrogen diarylheptanoid mediates estrogen receptor/Akt/glycogen synthase kinase 3β protein-dependent activation of the Wnt/β-catenin signaling pathway. J Biol Chem (2012) 0.94
E3 ubiquitin ligase-mediated regulation of bone formation and tumorigenesis. Cell Death Dis (2013) 0.94
Bone Loss Triggered by the Cytokine Network in Inflammatory Autoimmune Diseases. J Immunol Res (2015) 0.93
Bone density and brain atrophy in early Alzheimer's disease. J Alzheimers Dis (2009) 0.93
Inhibition of Ca²⁺/calmodulin-dependent protein kinase kinase 2 stimulates osteoblast formation and inhibits osteoclast differentiation. J Bone Miner Res (2013) 0.92
c-Abl promotes osteoblast expansion by differentially regulating canonical and non-canonical BMP pathways and p16INK4a expression. Nat Cell Biol (2012) 0.92
Endogenous tissue engineering: PTH therapy for skeletal repair. Cell Tissue Res (2011) 0.92
The hedgehog pathway conditions the bone microenvironment for osteolytic metastasis of breast cancer. Int J Breast Cancer (2011) 0.91
Reduced limbic and hypothalamic volumes correlate with bone density in early Alzheimer's disease. J Alzheimers Dis (2010) 0.91
Leptin increases osteoblast-specific osteocalcin release through a hypothalamic relay. Peptides (2009) 0.91
MicroRNAs regulate bone metabolism. J Bone Miner Metab (2013) 0.91
Sesamin stimulates osteoblast differentiation through p38 and ERK1/2 MAPK signaling pathways. BMC Complement Altern Med (2012) 0.91
Thyroid hormone actions in cartilage and bone. Eur Thyroid J (2012) 0.90
MicroRNAs as regulators of bone homeostasis and bone metastasis. Bonekey Rep (2014) 0.90
Anti-apoptotic molecule Bcl-2 regulates the differentiation, activation, and survival of both osteoblasts and osteoclasts. J Biol Chem (2009) 0.90
PIAS3 negatively regulates RANKL-mediated osteoclastogenesis directly in osteoclast precursors and indirectly via osteoblasts. Blood (2008) 0.90
The microtubule-associated protein DCAMKL1 regulates osteoblast function via repression of Runx2. J Exp Med (2013) 0.89
Global gene expression analysis of the interaction between cancer cells and osteoblasts to predict bone metastasis in breast cancer. PLoS One (2012) 0.89
Effects of bioactive lipids and lipoproteins on bone. Trends Endocrinol Metab (2013) 0.89
BMP signaling in mesenchymal stem cell differentiation and bone formation. J Biomed Sci Eng (2013) 0.89
The beneficial effect of Radix Dipsaci total saponins on bone metabolism in vitro and in vivo and the possible mechanisms of action. Osteoporos Int (2012) 0.88
The Wnt serpentine receptor Frizzled-9 regulates new bone formation in fracture healing. PLoS One (2013) 0.88
TM-25659 enhances osteogenic differentiation and suppresses adipogenic differentiation by modulating the transcriptional co-activator TAZ. Br J Pharmacol (2012) 0.88
In situ tissue regeneration: chemoattractants for endogenous stem cell recruitment. Tissue Eng Part B Rev (2013) 0.87
Bone remodeling: new aspects of a key process that controls skeletal maintenance and repair. Osteoporos Int (2004) 0.87
SOX9 protein induces a chondrogenic phenotype of mesangial cells and contributes to advanced diabetic nephropathy. J Biol Chem (2011) 0.86
Stem cell-mediated osteogenesis: therapeutic potential for bone tissue engineering. Biologics (2012) 0.86
Vitamin B₁₂-dependent taurine synthesis regulates growth and bone mass. J Clin Invest (2014) 0.86
Protein palmitoylation regulates osteoblast differentiation through BMP-induced osterix expression. PLoS One (2009) 0.86
Constitutively active parathyroid hormone receptor signaling in cells in osteoblastic lineage suppresses mechanical unloading-induced bone resorption. J Biol Chem (2007) 0.86
Evidence-based assessment of antiosteoporotic activity of petroleum-ether extract of Cissus quadrangularis Linn. on ovariectomy-induced osteoporosis. Ups J Med Sci (2009) 0.86
The orphan nuclear receptor SHP is a positive regulator of osteoblastic bone formation. J Bone Miner Res (2010) 0.86
Computational modeling of interactions between multiple myeloma and the bone microenvironment. PLoS One (2011) 0.86
Role of fibroblast growth factor 2 and Wnt signaling in anabolic effects of parathyroid hormone on bone formation. J Cell Physiol (2012) 0.86
Membrane trafficking in osteoblasts and osteoclasts: new avenues for understanding and treating skeletal diseases. Traffic (2012) 0.86
The role of subchondral bone remodeling in osteoarthritis: reduction of cartilage degeneration and prevention of osteophyte formation by alendronate in the rat anterior cruciate ligament transection model. Arthritis Rheum (2004) 2.22
Mapping of MST1 kinase sites of phosphorylation. Activation and autophosphorylation. J Biol Chem (2002) 1.97
The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorg Med Chem Lett (2008) 1.60
Mechanism of action of bisphosphonates. Curr Osteoporos Rep (2003) 1.43
Bisphosphonate mechanism of action. Curr Rheumatol Rep (2003) 1.39
PYK2 autophosphorylation, but not kinase activity, is necessary for adhesion-induced association with c-Src, osteoclast spreading, and bone resorption. J Biol Chem (2003) 1.38
Involvement of alpha(v)beta3 integrins in osteoclast function. J Bone Miner Metab (2007) 1.23
Nitrogen-containing bisphosphonate mechanism of action. Mini Rev Med Chem (2004) 1.20
Receptor tyrosine kinases inhibit bone morphogenetic protein-Smad responsive promoter activity and differentiation of murine MC3T3-E1 osteoblast-like cells. J Bone Miner Res (2003) 1.09
The LATS2/KPM tumor suppressor is a negative regulator of the androgen receptor. Mol Endocrinol (2004) 1.06
Estrogenic control of thermoregulation in ERalphaKO and ERbetaKO mice. Maturitas (2006) 0.99
Relative binding affinities of bisphosphonates for human bone and relationship to antiresorptive efficacy. Bone (2005) 0.97
Pathogenesis of osteoporosis. Endocrinol Metab Clin North Am (2003) 0.95
IL-1 regulates cytoskeletal organization in osteoclasts via TNF receptor-associated factor 6/c-Src complex. J Immunol (2002) 0.94
Control of rat tail skin temperature regulation by estrogen receptor-beta selective ligand. Maturitas (2009) 0.88
Rat tail skin temperature regulation by estrogen, phytoestrogens and tamoxifen. Maturitas (2004) 0.87
Nonpeptide alphavbeta3 antagonists. Part 11: discovery and preclinical evaluation of potent alphavbeta3 antagonists for the prevention and treatment of osteoporosis. J Med Chem (2004) 0.86
Nonpeptide alphavbeta3 antagonists. 8. In vitro and in vivo evaluation of a potent alphavbeta3 antagonist for the prevention and treatment of osteoporosis. J Med Chem (2003) 0.86
Antagonist-induced, activation function-2-independent estrogen receptor alpha phosphorylation. Mol Endocrinol (2005) 0.83
Identification of anabolic selective androgen receptor modulators with reduced activities in reproductive tissues and sebaceous glands. J Biol Chem (2009) 0.82
Regulatory mechanism of osteoclast activation. J Electron Microsc (Tokyo) (2003) 0.82
Distinct roles of p130Cas and c-Cbl in adhesion-induced or macrophage colony-stimulating factor-mediated signaling pathways in prefusion osteoclasts. Endocrinology (2003) 0.82
Agonist-like SERM effects on ERalpha-mediated repression of MMP1 promoter activity predict in vivo effects on bone and uterus. J Steroid Biochem Mol Biol (2008) 0.81
The discovery of MK-0674, an orally bioavailable cathepsin K inhibitor. Bioorg Med Chem Lett (2009) 0.81
M-CSF induces the stable interaction of cFms with alphaVbeta3 integrin in osteoclasts. Int J Biochem Cell Biol (2006) 0.80
Osteoporosis and bisphosphonates. J Bone Joint Surg Am (2003) 0.78
Non-peptide alpha(v)beta(3) antagonists: identification of potent, chain-shortened RGD mimetics that incorporate a central pyrrolidinone constraint. Bioorg Med Chem Lett (2003) 0.77
Non-peptide alpha(v)beta(3) antagonists. Part 4: potent and orally bioavailable chain-shortened RGD mimetics. Bioorg Med Chem Lett (2002) 0.77
Non-peptide alpha v beta 3 antagonists. Part 7: 3-Substituted tetrahydro-naphthyridine derivatives. Bioorg Med Chem Lett (2004) 0.76
Non-peptide alpha(v)beta(3) antagonists. Part 5: identification of potent RGD mimetics incorporating 2-aryl beta-amino acids as aspartic acid replacements. Bioorg Med Chem Lett (2002) 0.76
Nonpeptide alpha(v)beta(3) antagonists. Part 2: constrained glycyl amides derived from the RGD tripeptide. Bioorg Med Chem Lett (2002) 0.76
Cross-talk between an activator of nuclear receptors-mediated transcription and the D1 dopamine receptor signaling pathway. Pharmacol Biochem Behav (2005) 0.76
Nonpeptide alpha V beta 3 antagonists. Part 9: Improved pharmacokinetic profile through the use of an aliphatic, des-amide backbone. Bioorg Med Chem Lett (2004) 0.75
Development of selective androgen receptor modulators and their therapeutic applications. Zhonghua Nan Ke Xue (2002) 0.75
Nonpeptide alpha(v)beta3 antagonists: identification of potent, chain-shortened 7-oxo RGD mimetics. Bioorg Med Chem Lett (2005) 0.75
Non-peptide alpha(v)beta(3) antagonists. Part 3: identification of potent RGD mimetics incorporating novel beta-amino acids as aspartic acid replacements. Bioorg Med Chem Lett (2002) 0.75
Nonpeptide alpha V beta 3 antagonists. Part 10: In vitro and in vivo evaluation of a potent 7-methyl substituted tetrahydro-[1,8]naphthyridine derivative. Bioorg Med Chem Lett (2004) 0.75